InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,469.30
(
0.39%
)
US TECH 100
19,178.00
(
1.16%
)
Dow Jones
39,112.16
(
-0.76%
)
Brent Oil
84.19
(
-1.27%
)
Bitcoin
61,802.97
(
0.00%
)
Post# of 252347
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119916
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: turtlepower post# 162078

Monday, 06/03/2013 6:40:03 PM

Monday, June 03, 2013 6:40:03 PM

Post# of 252347
PTLA—There’s nothing wrong with Betrixaban per se, but it’s not differentiated from Eliquis (or Xarelto) and it’s very late to market even in the best-case scenario. That’s why MRK pulled out of the partnership to develop Betrixaban two years ago (#msg-61300408).

If PTLA would scrap Betrixaban and focus only on extracting maximum value for PRT-4445, I would be more inclined to invest.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up